ProCE Banner Activity

Immunotherapy in Nonmetastatic NSCLC

Slideset Download
Download this slideset from a live CCO symposium for an expert overview of the evolving immunotherapy landscape for early-stage resectable and stage III unresectable NSCLC.

Released: June 07, 2022

Expiration: June 06, 2023

Share

Faculty

Natasha Leighl

Natasha Leighl, MD, MMSc, FRCPC, FASCO

Lung Medical Oncology Site Lead
OSI Pharmaceuticals Foundation Chair
Princess Margaret Cancer Centre
Professor of Medicine
University of Toronto
Toronto, Canada

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Lilly

Merck Sharp & Dohme Corp.

Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme

Faculty Disclosure

Primary Author

Natasha Leighl, MD, MMSc, FRCPC, FASCO

Lung Medical Oncology Site Lead
OSI Pharmaceuticals Foundation Chair
Princess Margaret Cancer Centre
Professor of Medicine
University of Toronto
Toronto, Canada

Natasha Leighl, MD, MMsc, FRCPC, FASCO, has disclosed that she has received funds for research support from Amgen, Array, AstraZeneca, Bayer, Bristol Myers Squibb, Eli Lilly, EMD Serono, Guardant Health, Inivata, MSD, Novartis, Pfizer, Roche, and Takeda and consultant/advisor/ speaker fees for Amgen, Bristol Myers Squibb, GlaxoSmithKline, MSD, Novartis, Puma Biotechnology, Sanofi Genzyme, and Takeda.